Alopecia Areata Key Players, Recent Strategic Partnerships, Market Entry and Expansion Strategies, IP Valuation, Leadership and Governance, Risk Mitigation

Alopecia Areata Market Companies and Shares Growth

The global alopecia areata market size is calculated at USD 3.32 billion in 2024 and is expected to be worth USD 6.92 billion by 2034, expanding at a CAGR of 7.6% from 2024 to 2034.

The alopecia areata companies are:

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline Plc.
• Johnson & Johnson Services Inc.
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• AstraZeneca
• Abbott Laboratories

Competitive Landscape

The competitive landscape for alopecia areata refers to the different companies and treatments available for this condition. Just like other brands of cars compete in the automobile market, various pharmaceutical companies offer products to help people with alopecia areata. They might have different pills, creams, or other treatments. These companies compete to create the best and most effective options for people dealing with hair loss due to alopecia areata.

Latest Announcements by Industry Leaders

Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer, commented on the US FDA approval of LITFULO that it is an important treatment advancement for alopecia areata that had no treatment options for adolescents and very limited options for adults. He added that both adolescents and adults will have an opportunity to achieve significant scalp hair regrowth.

Recent Developments

• In May 2024, researchers from MIT, Brigham and Women’s Hospital, and Harvard Medical School developed a microneedle patch, a potential new treatment, for alopecia areata. The patch could reverse hair loss by delivering immune-regulating molecules and can teach T-cells to not attack hair follicles, helping hair to regrow.
• In March 2023, Sun Pharmaceuticals revealed they would showcase findings from a phase 3 clinical study concerning deuruxolitinib, an oral medication designed to assist individuals with alopecia areata in regenerating hair on their scalp.
• In March 2023, Sun Pharmaceuticals revealed they would showcase findings from a phase 3 clinical study concerning deuruxolitinib, an oral medication designed to assist individuals with alopecia areata in regenerating hair on their scalp.
• In June 2023, Pfizer got approval from the FDA for LITFULOTM (ritlecitinib), a pill to treat severe alopecia areata in people aged 12 and above. This approval made LITFULOTM a more advanced option for those with this condition.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com